Suppr超能文献

在绷带接触镜存在的情况下使用 Cenegermin。

Use of Cenegermin in the Presence of Bandage Contact Lenses.

机构信息

Virginia Eye Consultants/CVP Physicians, Norfolk, VA.

Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, VA.

出版信息

Cornea. 2022 Jan 1;41(1):78-82. doi: 10.1097/ICO.0000000000002797.

Abstract

PURPOSE

The aim of this study was to characterize the outcomes of eyes with neurotrophic keratitis (NK) treated with a course of cenegermin-bkbj in the presence of a bandage contact lens (BCL).

METHODS

A retrospective chart review of all eyes with a clinical diagnosis of NK treated with cenegermin-bkbj was performed between 2018 and 2020. Inclusion criteria included cenegermin-bkbj treatment with a BCL in place. Demographics, etiology, visual acuity, pretreatment and posttreatment corneal sensation, and treatment outcomes were assessed.

RESULTS

There were 18 eyes of 16 patients (69% female) with NK treated with cenegermin-bkbj while having a BCL in place. After cenegermin-bkbj treatment, presence of corneal sensation significantly increased from 7% of eyes to 79% of eyes (P < 0.0001). There was also a significant increase in the number of quadrants with corneal sensation (mean of 0.1 quadrants increased to 1.6 quadrants, P =0.0005). Six of 10 eyes (67%; P = 0.004) with a persistent epithelial defect (PED) experienced complete resolution at the conclusion of treatment, while 3 additional eyes experienced a decrease in the defect size. Despite all 18 eyes necessitating a chronic BCL before cenegermin-bkbj treatment, 4 were able to maintain their epithelium without a BCL after treatment for at least some period.

CONCLUSIONS

Cenegermin-bkbj treatment for NK with a BCL in place demonstrated improvement in corneal sensation, epithelial defect size, and fluorescein staining. In eyes demonstrating previous ocular surface decompensation with discontinuation of a BCL, maintenance of BCL use during treatment with cenegermin-bkbj may be considered.

摘要

目的

本研究旨在描述在绷带接触镜(BCL)存在的情况下,使用神经营养性角膜炎(NK)治疗课程中的 Cenegermin-bkbj 的治疗结果。

方法

对 2018 年至 2020 年期间使用 Cenegermin-bkbj 治疗的临床诊断为 NK 的所有眼睛进行了回顾性图表审查。纳入标准包括使用 Cenegermin-bkbj 治疗并放置 BCL。评估人口统计学、病因、视力、治疗前和治疗后角膜感觉以及治疗结果。

结果

共有 16 名患者(69%为女性)的 18 只眼睛因 NK 接受了 Cenegermin-bkbj 治疗,同时放置了 BCL。在 Cenegermin-bkbj 治疗后,角膜感觉的存在从 7%的眼睛显著增加到 79%的眼睛(P < 0.0001)。角膜感觉的象限数量也显著增加(平均增加了 0.1 个象限到 1.6 个象限,P = 0.0005)。10 只眼睛中有 6 只(67%;P = 0.004)持续上皮缺损(PED)在治疗结束时完全缓解,而另外 3 只眼睛缺损大小减小。尽管在接受 Cenegermin-bkbj 治疗之前,所有 18 只眼睛都需要长期使用 BCL,但在治疗后,有 4 只眼睛至少在一段时间内能够在没有 BCL 的情况下维持其上皮。

结论

在 BCL 存在的情况下,使用 Cenegermin-bkbj 治疗 NK 可改善角膜感觉、上皮缺损大小和荧光素染色。对于先前因停用 BCL 而导致眼表面失代偿的眼睛,可以考虑在使用 Cenegermin-bkbj 治疗期间继续使用 BCL。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验